A Review of Synthetic Access to Therapeutic Compounds Extracted from Psilocybe

Serreau, Raphaël; Amirouche, Ammar; Benyamina, Amine; Berteina-Raboin, Sabine

doi:10.3390/ph16010040

Open AccessReview

A Review of Synthetic Access to Therapeutic Compounds Extracted from Psilocybe

by

Raphaël Serreau

^1,2

,

Ammar Amirouche

³,

Amine Benyamina

³ and

Sabine Berteina-Raboin

^4,*

¹

Unité de Recherche PSYCOMADD, APHP Université Paris Saclay, Hôpital Paul-Brousse, 12 Avenue Paul Vaillant Couturier, 94804 Villejuif, France

²

Addictologie EPSM Georges DAUMEZON, GHT Loiret, 1 Route de Chanteau, 45400 Fleury les Aubrais, France

³

Unité de Recherche PSYCOMADD-Psychiatrie Comorbidités Addictions, APHP Université Paris Saclay, Hôpital Paul-Brousse, 12 Avenue Paul Vaillant Couturier, 94804 Villejuif, France

⁴

Institut de Chimie Organique et Analytique (ICOA), Université d’Orléans, UMR-CNRS 7311, BP 6759, Rue de Chartres, CEDEX 2, 45067 Orléans, France

^*

Author to whom correspondence should be addressed.

Pharmaceuticals 2023, 16(1), 40; https://doi.org/10.3390/ph16010040

Submission received: 25 November 2022 / Revised: 14 December 2022 / Accepted: 23 December 2022 / Published: 28 December 2022

(This article belongs to the Special Issue Heterocyclic Compounds and Their Application in Therapy)

Download

Browse Figures

Versions Notes

Abstract

Psychedelics are used for various pathologies of the central nervous system and are currently the subject of much research, some of which relates to the compounds contained in various Psilocybe-type hallucinogenic mushrooms. It is difficult, however, to obtain and purify sufficient quantities of these compounds from fungi to carry out biological studies, hence the need to develop simple and efficient synthetic routes. We review here the various syntheses used to obtain these molecules, focusing first on the classic historical syntheses, then the use of more recent metallo-catalyzed couplings and finally the known biocatalytic methods for obtaining these molecules. Other access routes are certainly possible and should be the subject of future research given the therapeutic interest of these compounds.

Keywords: psychedelics; Psilocybe mushrooms; tryptamines; psilocybin; psilocin; synthetic access; clinical research

Share and Cite

MDPI and ACS Style

Serreau, R.; Amirouche, A.; Benyamina, A.; Berteina-Raboin, S. A Review of Synthetic Access to Therapeutic Compounds Extracted from Psilocybe. Pharmaceuticals 2023, 16, 40. https://doi.org/10.3390/ph16010040

AMA Style

Serreau R, Amirouche A, Benyamina A, Berteina-Raboin S. A Review of Synthetic Access to Therapeutic Compounds Extracted from Psilocybe. Pharmaceuticals. 2023; 16(1):40. https://doi.org/10.3390/ph16010040

Chicago/Turabian Style

Serreau, Raphaël, Ammar Amirouche, Amine Benyamina, and Sabine Berteina-Raboin. 2023. "A Review of Synthetic Access to Therapeutic Compounds Extracted from Psilocybe" Pharmaceuticals 16, no. 1: 40. https://doi.org/10.3390/ph16010040

APA Style

Serreau, R., Amirouche, A., Benyamina, A., & Berteina-Raboin, S. (2023). A Review of Synthetic Access to Therapeutic Compounds Extracted from Psilocybe. Pharmaceuticals, 16(1), 40. https://doi.org/10.3390/ph16010040

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Menu

A Review of Synthetic Access to Therapeutic Compounds Extracted from Psilocybe

Abstract

Share and Cite

Article Metrics

Article Access Statistics

Further Information

Guidelines

MDPI Initiatives

Follow MDPI